E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Effect of respiration on venous return and stroke volume in cardiac tamponade
Ivor T. Gabe,Dean T. Mason,James H. Gault,John Ross,R. Zelis,C. J. Mills,Eugene Braunwald,John Shillingford +7 more
TL;DR: Findings point to competition for space by the ventricles in the distended pericardial sac as being the major factor in the production of pulsus paradoxus.
Journal ArticleDOI
The krypton85 inhalation test for the detection of left-to-right shunts.
TL;DR: Radioactive krypton (Kr85) has been found to provide substantial advantages over other gases and it has therefore been employed routinely in this laboratory for the past several years and it is the purpose of this communication to analyse the results obtained from the application of the Kr85 inhalation test in 323 patients.
Journal ArticleDOI
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial
Arman Qamar,Robert P. Giugliano,Erin A. Bohula,Jeong-Gun Park,Petr Jarolim,Sabina A. Murphy,Michael A. Blazing,Robert M. Califf,Christopher P. Cannon,Eugene Braunwald,David A. Morrow +10 more
TL;DR: A biomarker-based strategy identifies a gradient of risk among patients post-ACS, offering the potential to identify higher-risk patients with a correspondingly high absolute benefit from the addition of ezetimibe to statin therapy.
Journal ArticleDOI
Effects of acutely induced ischemic heart failure on myocardial high energy phosphate stores.
TL;DR: The results indicate that acute ischemic heart failure is not initiated by a detectable depression in total myocardial ATP stores, and this should not be interpreted as a cause for concern.
Journal ArticleDOI
Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II).
Bernard J. Gersh,James H. Chesebro,Eugene Braunwald,Costas T. Lambrew,Eugene R. Passamani,Rachel E. Solomon,Allan M. Ross,Richard N. Ross,Michael L. Terrin,Genell L. Knatterud +9 more
TL;DR: The increased mortality rate with bypass surgery after thrombolytic therapy, particularly in patients undergoing operation within 24 h of coronary angioplasty or during the involving phase of infarction, must be balanced against the excellent 1-year prognosis and perioperative survivors, who are in general a group at higher risk of death or recurrent infarctions.